Andrew Hopkins ^Leaders

Andrew Hopkins, as the founder and CEO of Exscientia, leads a global pharmatech company at the forefront of using AI for drug discovery. Exscientia focuses on encoding, automating, and transforming every stage of the drug design and development process by blending AI with experimental innovation. Under Hopkins' leadership, the company has achieved significant milestones, including delivering the first three AI-designed drugs to enter clinical trials and proving the efficacy of AI in improving clinical outcomes in oncology. Andrew's vision drives Exscientia's mission to engineer patient-centric drug candidates more efficiently, with a proven track record of accelerating pre-clinical drug discovery.